U.S. Markets closed

Gilead Sciences, Inc. (GILD)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
64.50-0.06 (-0.09%)
At close: 4:00PM EDT
People also watch
CELGBIIBAMGNBMYREGN
Interactive chart
Previous Close64.56
Open64.37
Bid64.50 x 400
Ask64.59 x 2000
Day's Range64.31 - 64.75
52 Week Range63.88 - 88.85
Volume3,646,119
Avg. Volume7,827,619
Market Cap84.28B
Beta0.99
PE Ratio (TTM)6.82
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield2.08 (3.22%)
Ex-Dividend Date2017-03-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Which Biotechs Benefit Most Under Trump's Tax Reform Vision?
    Investor's Business Daily21 hours ago

    Which Biotechs Benefit Most Under Trump's Tax Reform Vision?

    Regeneron, Gilead and Biogen will benefit the most among biotechs under Trump's proposed tax reform, a measure that would cut the corporate tax rate by 20%.

  • Market Realistyesterday

    TAF-Based Regimens Could Boost Gilead Sciences’ Revenue Growth

    Gilead Sciences’ (GILD) tenofovir alafenamide fumarate (or TAF) based regimens have seen high adoption rates in the US and European markets.

  • American City Business Journalsyesterday

    Gilead Sciences CFO named ‘Financial Woman of the Year’

    The Financial Women of San Francisco selected Gilead Sciences Chief Financial Officer Robin Washington as its 2017 Financial Woman of the Year. Washington was also recognized this week as the recipient of the lifetime achievement award at the “2017 Bay Area CFO of the Year Awards,” a program conducted by Larkin Street Youth Services in partnership with the Business Times. In accepting her award this week, it was clear that Washington spent a good portion of her career staying one step ahead of Oracle’s M&A department.